Furthermore, in vitro and in vivo studies support this claim, showing that anti-CS1 antibodies inhibit MM cell binding to stromal cells in the bone marrow and induce cellular cytotoxicity against the myeloma cells [78,79]. Here, SLAMF7 is linked to Miyoshi myopathy.